Biomarker Analysis of Central Nervous System Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02692898|
Recruitment Status : Terminated
First Posted : February 26, 2016
Last Update Posted : November 19, 2019
The number of people who get tumors of the brain or central nervous system (CNS) is lower than other cancers. But these tumors cause a higher rate of serious effects and even death. Researchers want to test existing samples of tissue from these tumors to learn more about them. This may lead to better treatment.
To study stored samples of CNS tumors to learn more about the tumors and explore new ways to diagnose them.
The study will use tissue samples already collected at NIH from people with brain or CNS tumors.
The participants will have given their consent in a previous study.
Researchers will review the tissue samples and any data collected about them.
Researchers will do lab tests and scans on the samples.
All data will be kept secure.
|Condition or disease|
|Central Nervous System Neoplasms Primary Brain Neoplasms Neoplasms, Brain Cancer of the Brain Brain Cancer|
|Study Type :||Observational|
|Actual Enrollment :||12 participants|
|Official Title:||Biomarker Analysis of Central Nervous System Tumors|
|Study Start Date :||February 25, 2016|
|Actual Primary Completion Date :||November 15, 2019|
|Actual Study Completion Date :||November 15, 2019|
Archived CNS neoplasm specimens, in which primary diagnostic studies are complete, and for which there is excess tissue for analysis in the form of unstained slides or paraffin blocks
- Tumor profile of CNS Tumors [ Time Frame: completion of study ]To study archived specimens of CNS tumors from the NCI CCR Laboratory of Pathology to explore potential new biomarkers for diagnosis and to better understand CNS tumor pathogenesis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02692898
|United States, Maryland|
|National Cancer Institute (NCI), 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Terri S Armstrong, C.R.N.P.||National Cancer Institute (NCI)|